drug

mirvetuximab soravtansine

1 story · latest Jul 8, 2026

Status: FDA approved Nov 2022 · BLA761310
Brands: Elahere, Mirv
Code: IMGN853
Trials: 5 registered trials in coverage

Relationships

Developed by AbbVie

Timeline

AbbVie registers two real-world studies for atogepant and mirvetuximab soravtansine-gynx

Jul 8Weekly roundup, 2 itemsAbbVie atogepant

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.